Ab­b­Vie pe­ti­tions trade com­mis­sion to ban Alvotech's Hu­mi­ra biosim­i­lar; Cy­to­ki­net­ics li­cens­es heart drug to Chi­nese part­ner

The Ab­b­Vie/Alvotech de­ba­cle on a Hu­mi­ra biosim­i­lar has tak­en yet an­oth­er turn — es­ca­lat­ing ten­sions be­tween the two biotechs.

As first re­port­ed by STAT News, the phar­ma gi­ant filed a com­plaint with the US In­ter­na­tion­al Trade Com­mis­sion on Fri­day, try­ing to pre­vent Alvotech from sell­ing a low­er cost ver­sion of Ab­b­Vie’s Hu­mi­ra, an an­ti-TNF drug that treats rheuma­toid arthri­tis, anky­los­ing spondyli­tis and Crohn’s dis­ease, among oth­er ail­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER